Skip to main content

Table 4 Risk of SPC by first and second cancer site among male patients, France 1989–2004 (N = 160,807)

From: The effect of patient characteristics on second primary cancer risk in France

First cancer site Second cancer site O E PYR SIRa EARa,b (95% CI)
Lip Lung, bronchus and trachea 27 9.52 4,081 2.84 42.8 (20.3-72.9)
  Oesophagus 7 1.79   3.91 12.8 (2.5-31.0)
Head and neck Lung, bronchus and trachea 663 76.15 38,731 8.71 151.5 (138.7-165.1)
  Head and neckc 405 24.54   16.50 98.2 (88.3-108.9)
  Oesophagus 269 13.79   19.51 65.9 (57.8-74.7)
  Larynx 76 10.74   7.07 16.8 (12.7-21.8)
  Colorectum 109 60.09   1.81 12.6 (7.6-18.4)
  Liver, primary 62 17.04   3.64 11.6 (7.9-16.1)
  Bladder 53 24.13   2.20 7.5 (4.0-11.7)
  Kidney 35 17.32   2.02 4.6 (1.8-8.1)
  Pancreas 26 11.03   2.36 3.9 (1.5-7.0)
  Stomach 29 14.27   2.03 3.8 (1.3-7.1)
Oesophagus Head and neck 92 6.29 7,367 14.63 116.3 (92.1-144.6)
  Lung, bronchus and trachea 71 16.70   4.25 73.7 (52.6-98.9)
  Larynx 16 2.25   7.11 18.7 (9.4-32.2)
  Colorectum 25 14.51   1.72 14.2 (2.3-30.4)
  Stomach 10 3.72   2.69 8.5 (1.5-19.9)
  Bladder 12 5.96   2.01 8.2 (0.3-20.4)
Colorectum Colorectumc 174 119.63 97,268 1.45 5.6 (3.0-8.5)
  Lung, bronchus and trachea 279 240.30   1.16 4.0 (0.7-7.5)
  Bladder 136 104.92   1.30 3.2 (0.9-5.8)
Larynx Lung, bronchus and trachea 310 44.71 19,900 6.93 133.3 (116.5-151.7)
  Head and neck 138 15.78   8.75 61.4 (50.3-74.0)
  Oesophagus 64 7.59   8.43 28.3 (21.0-37.3)
  Bladder 46 16.25   2.83 15.0 (8.8-22.7)
  Colorectum 62 39.40   1.57 11.4 (4.1-20.1)
  Liver, primary 22 10.72   2.05 5.7 (1.5-11.4)
  Stomach 19 9.27   2.05 4.9 (1.1-10.3)
  Pancreas 14 6.96   2.01 3.5 (0.3-8.3)
Lung, bronchus and trachea Head and neck 127 31.83 41,162 3.99 23.1 (18.0-29.0)
  Bladder 105 34.29   3.06 17.2 (12.5-22.5)
  Oesophagus 55 15.65   3.51 9.6 (6.3-13.6)
  Colorectum 121 84.25   1.44 8.9 (3.9-14.7)
  Larynx 45 12.08   3.73 8.0 (5.0-11.7)
  Kidney 45 21.47   2.10 5.7 (2.8-9.4)
  Leukaemia 30 16.07   1.87 3.4 (1.0-6.5)
Melanoma of skin Leukaemia 19 6.22 20,881 3.06 6.1 (2.5-11.2)
Prostate Colorectum 830 692.73 230,582 1.20 6.0 (3.5-8.5)
  Bladder 406 291.02   1.40 5.0 (3.3-6.8)
Testis Kidney 10 2.38 19,448 4.20 3.9 (1.2-8.2)
Bladder Lung, bronchus and trachea 295 94.45 38,002 3.12 52.8 (44.2-62.2)
  Prostate 398 257.66   1.54 36.9 (26.9-47.7)
  Head and neck 55 27.02   2.04 7.4 (3.8-11.7)
  Larynx 28 10.96   2.55 4.5 (2.0-7.8)
  Stomach 38 23.71   1.60 3.8 (0.8-7.5)
Kidney Prostate 269 162.00 28,385 1.66 37.7 (26.7-49.7)
  Bladder 39 24.55   1.59 5.1 (1.1-10.1)
Thyroid gland Prostate 34 20.08 7,369 1.69 18.9 (4.7-37.2)
  Leukaemia 5 1.50   3.33 4.7 (0.1-13.8)
Hodgkin's disease Lung, bronchus and trachea 23 5.72 8,338 4.02 20.7 (10.6-34.5)
  Non-Hodgkin’s lymphoma 6 1.33   4.50 5.6 (1.0-14.1)
  Oesophagus 4 0.93   4.29 3.7 (0.2-11.2)
Non-Hodgkin’s lymphoma Lung, bronchus and trachea 76 46.84 26,008 1.62 11.2 (5.0-18.6)
  Leukaemia 21 8.50   2.47 4.8 (1.7-9.1)
  Bladder 30 17.70   1.70 4.7 (1.0-9.7)
  Stomach 18 10.21   1.76 3.0 (0.2-7.0)
Chronic lymphatic leukaemia Lung, bronchus and trachea 56 27.69 11,261 2.02 25.1 (13.0-40.0)
Colorectum 41 27.78   1.48 11.7 (1.5-24.7)
  Hodgkin’s disease 4 0.39   10.26 3.2 (0.6-8.7)
  1. SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
  2. aAll P < .05.
  3. bNumber of excess cancers per 10,000 person-years at risk.
  4. cSPC occurring in a different subsite as the first primary cancer.